Patents Issued in January 12, 2016
  • Patent number: 9233092
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustained enhancement effect on the PPI activity compared to the non-derivatized acid molecules. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: January 12, 2016
    Assignee: Vecta, Ltd.
    Inventors: Michael Marash, Aleksey Kostadinov, Tal Atarot
  • Patent number: 9233093
    Abstract: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: January 12, 2016
    Assignee: MOCHIDA PHARMACEUTICALS CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Patent number: 9233094
    Abstract: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: January 12, 2016
    Assignee: Medigene AG
    Inventors: Axel Mescheder, Matthias Karrasch
  • Patent number: 9233095
    Abstract: Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: January 12, 2016
    Assignees: University of Rochester, Board of Regents of the University of Nebraska, Temple University—Of the Commonwealth System of Higher Education
    Inventors: Paul M. Dunman, Patrick D. Olson, Wayne Childers
  • Patent number: 9233096
    Abstract: The present invention relates to methods of isolating flavonoids from Euphorbia cuneata, and a pharmaceutical composition comprising the flavonoids or the extracts or both of them for a use as anti-ulcer agent. The present invention further relates to a method of providing an anti-ulcer treatment to an animal in need thereof comprising administering to the animal a compound selected from 4?-methoxy-luteolin-7-O-rhamnoglucoside and aromadendrin. A method of providing an anti-ulcer treatment to an animal in need thereof comprising administering to the animal a compound selected from 4?-methoxy-luteolin-7-O-rhamnoglucoside and aromadendrin, in which the compound(s) are isolated from Euphorbia cuneata.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: January 12, 2016
    Assignee: King Saud University
    Inventors: Amani S. Awaad, Reham Moustafa El-Meligy
  • Patent number: 9233097
    Abstract: The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: January 12, 2016
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A. C. L. Stone, William C. Weimers, Gopi Krishna Kasi, Peter N. K. Samuel, Tove Bolken, Dennis E. Hruby
  • Patent number: 9233098
    Abstract: The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 12, 2016
    Assignee: KBP BIOSCIENCES CO., LTD.
    Inventors: Yan Zhang, Min Zhang, Hoyin Lo
  • Patent number: 9233099
    Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolizm using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: January 12, 2016
    Assignees: University of Cincinnati, Children's Hospital Medical Center
    Inventors: Joseph F. Clark, Antonius J. de Grauw
  • Patent number: 9233100
    Abstract: This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: January 12, 2016
    Assignee: MERIAL, INC.
    Inventors: Mark David Soll, Diane Larsen, Susan Mancini Cady, Peter Cheifetz, Izabela Galeska, Saijun Gong
  • Patent number: 9233101
    Abstract: A new class of anti-microbial agents and methods for preventing or reducing the risk of sexually transmitted infections and/or diseases is provided. Preferably, these anti-microbial agents are also contraceptive and, thus, also prevent or reduce the risk of unplanned pregnancies. The anti-microbial agents comprise a delivery vector having anti-microbial activity (and preferably contraceptive activity) coupled with a nitric oxide donor moiety.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: January 12, 2016
    Assignee: Rush University Medical Center
    Inventors: Robert Anthony Anderson, Jr., Calvin J. Chany, II
  • Patent number: 9233102
    Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 12, 2016
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
  • Patent number: 9233103
    Abstract: The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: January 12, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Ronald D. Lee
  • Patent number: 9233104
    Abstract: Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 12, 2016
    Assignee: Samumed, LLC
    Inventors: John Hood, Sunil Kumar KC, David Mark Wallace
  • Patent number: 9233105
    Abstract: The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: January 12, 2016
    Assignee: Adare Pharmaceuticals S.R.L.
    Inventors: Luigi Mapelli, Flavio Fabiani, Luigi Boltri, Paolo Gatti, Mauro Serratoni, Roberto Cassanmagnago
  • Patent number: 9233106
    Abstract: The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: January 12, 2016
    Assignee: CORNELL RESEARCH FOUNDATION, INC.
    Inventors: George P. Hess, Moataz M. Gadalla
  • Patent number: 9233107
    Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
    Type: Grant
    Filed: September 13, 2008
    Date of Patent: January 12, 2016
    Assignee: Biogen MA Inc.
    Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
  • Patent number: 9233108
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: January 12, 2016
    Assignee: ALMIRALL, S.A.
    Inventors: Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • Patent number: 9233109
    Abstract: Briefly described, embodiments of this disclosure, among others, include compositions, pharmaceutical compositions, methods of treating nicotine dependence, methods of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorder, method of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorders, and the like.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: January 12, 2016
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Roger Lee Papke, Adriaan Willem Bruijnzeel, Sara Jo Nixon, William Kem, Ferenc Soti
  • Patent number: 9233110
    Abstract: The invention encompasses nanoparticle assemblies and methods for preparing nanoparticle and compositions comprising such nanoparticles for use in topical or skin applications. The invention further encompasses methods of complexing various molecular and cellular entities to the nanoparticles using the resulting nanoparticles of the invention as delivery devices. The nanoparticles can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of a complexed agent in vivo, protecting a complexed agent against degradation, increasing skin penetration and retention of drugs, and enhancing the water solubility/dispersibility of a drug or other agent.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: January 12, 2016
    Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni, Satheesh K. Podaralla, Mohammed Alqahtani
  • Patent number: 9233111
    Abstract: The present invention describes new pyrrolo pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel pyrrolo pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: July 7, 2012
    Date of Patent: January 12, 2016
    Assignee: NOVARTIS AG
    Inventors: Richard Heng, Elizabeth Kate Hoegenauer, Guido Koch, Robert Alexander Pulz, Anna Vulpetti, Rudolf Waelchli
  • Patent number: 9233112
    Abstract: A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: January 12, 2016
    Assignee: LUPIN LIMITED
    Inventors: Shrenik Annasaheb Kole, Bharat Raghunath Metkar, Makarand Krishnakumar Avachat
  • Patent number: 9233113
    Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: January 12, 2016
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventor: David Bar-Or
  • Patent number: 9233114
    Abstract: Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 12, 2016
    Assignee: Buriva, LLC
    Inventor: Rhett Sean Daniels
  • Patent number: 9233115
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: January 12, 2016
    Assignee: Millennium Pharmaceuticals Inc.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Patent number: 9233116
    Abstract: Composition containing iridoids such as morroniside and loganin, the use thereof in preparing medicaments for preventing and treating neurologic demyelinating diseases, and the method thereof in treating diseases related to neurologic demyelinating lesions are disclosed by the present application.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 12, 2016
    Assignee: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Lin Li, Linlin Yin, Lan Zhang, Wen Wang, Ruyi Zhang
  • Patent number: 9233117
    Abstract: Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 12, 2016
    Assignee: Galderma S. A.
    Inventors: Jean Jacovella, Jean-Paul Chappuis, Nathalie Sordello Wagner, Michael Graeber, Alexandre Kaoukhov, Laurence Salin, Michel Poncet, Philippe Briantais, Khaled Benkali
  • Patent number: 9233118
    Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 12, 2016
    Assignee: Galderma S.A.
    Inventors: Jean Jacovella, Jean-Paul Chappuis, Alexandre Kaoukhov, Michael Graeber, Michel Poncet, Philippe Briantais, Laurence Salin
  • Patent number: 9233119
    Abstract: Elevated high mobility group A (HMGA) protein expression in human cancer cells, and especially human pancreatic cancer cells, is correlated with resistance to the chemotherapy agent gemcitabine. The present invention uses HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine. Significant increases in cell death in AT-sDNA transfected cells compared to non AT-rich sDNA treated cells were observed in both cell lines. The data indicates the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in human cancer treatment, and in particular human pancreatic cancer treatment.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 12, 2016
    Inventor: Michael A. Kennedy
  • Patent number: 9233120
    Abstract: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: January 12, 2016
    Assignee: JYANT TECHNOLOGIES
    Inventors: James W. Lillard, Shailesh Singh, Rajesh Singh
  • Patent number: 9233121
    Abstract: Compositions and methods for treating, detecting, and diagnosing cancer are disclosed.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: January 12, 2016
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Surinder K. Batra, Moorthy P. Ponnusamy
  • Patent number: 9233122
    Abstract: An object of the present invention is to provide an agent for suppressing elevation of blood alcohol concentration and a method for suppressing elevation of blood alcohol concentration, the agent and the method enabling prevention of an intoxication state upon drinking and further prevention of hepatic dysfunctions due to drinking such as fatty liver. Provided are an agent for suppressing elevation of blood alcohol concentration, comprising a dextrin as an active ingredient, and a method for suppressing elevation of blood alcohol concentration, comprising, when alcohol is ingested, ingesting 0.5 parts by mass or more of a digestible dextrin and/or an indigestible dextrin relative to 1 part by mass of the ingested alcohol.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: January 12, 2016
    Assignee: MATSUTANI CHEMICAL INDUSTRY CO., LTD.
    Inventors: Shoko Miyazato, Yuka Kishimoto
  • Patent number: 9233123
    Abstract: Ophthalmic compositions including lubricant agent, deturgescent agent, glycosaminoglycan, and water are used to preserve tissue in vitro; for example, ocular tissue, especially a cornea, thereby facilitating subsequent transplant, especially of a complete cornea. Preferably, the ophthalmic composition and tissue are stored at about 0° C. to about 40° C. The ophthalmic solution may be replaced on either a continuous basis or batch exchanged. The volume of ophthalmic solution per individual cornea being preserved would be from about 50 ml to about 500 ml.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: January 12, 2016
    Inventor: Richard L. Lindstrom
  • Patent number: 9233124
    Abstract: The invention relates to a biomaterial containing calcium phosphate, in particular hydroxyapatite or a material containing hydroxyapatite, such as biphasic calcium phosphates and calcium phosphate cements, and to the use thereof for the production of an implant or for fitting a prosthesis for the purpose of bone tissue regeneration.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: January 12, 2016
    Assignees: Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire De Nice
    Inventors: Thierry Balaguer, Nathalie Rochet, Georges Carle
  • Patent number: 9233125
    Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, ?FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of ?FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: January 12, 2016
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Eduardo Davila, Koji Tamada
  • Patent number: 9233126
    Abstract: The present invention relates to a method of treating functional disability and/or pain associated with joints, tendons or connective tissue diseases, disorders or injuries comprising oral administration of a composition comprising heterologous platelet-rich plasma. The invention also relates to pharmaceutical compositions and nutritional compositions comprising heterologous platelet-rich plasma and uses thereof.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 12, 2016
    Assignee: OPKO LAB EUROPE SL
    Inventors: Julian Agut Sanchez, Carlos Fernandez Navarro, Joan Cos Trullas, Laura Ocana Safont, Elsa Genove Corominas
  • Patent number: 9233127
    Abstract: The present invention provides for enhancing engraftment by co-infusing at least two partially HLA matched umbilical cord blood (“UCB”) units. The invention further provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention further provides for enhancing the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway and that C3a and LL-37 are useful for this method. It is also disclosed herein that fragments of C3a (e.g., des-Arg) are effective in the methods of the invention, including enhancing homing of HSPCs to BM. The invention further encompasses the disclosure herein of NFAT1 regulation post-transcriptionally by both mir-184 and IFN-?. The present invention further provides for measuring and using differences between UCB and adult CD4+/45RA+ T-cells as a means of defining strategies to enhance optimal allogeneic stem cell transplantation outcomes.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: January 12, 2016
    Assignee: University of Virginia Patent Foundation
    Inventors: Mary J. Laughlin, Mariusz Z. Ratajczak, Claudio Brunstein
  • Patent number: 9233128
    Abstract: Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. When the cryptotanshinone is treated to the MSCs, the differentiation into osteoblasts is stimulated, and thus osteogenesis of a patient may be stimulated by directly transplanting the differentiation-induced MSCs to the patient. Accordingly, the composition or osteogenesis stimulator may be used to treat patients having disability requiring stimulation of osteogenesis such as osteoporosis, bone fracture, bone grafting including alveolar bone grafting for implant placement, or other bone defects.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 12, 2016
    Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Jin Hee Shin, Kyung Soo Kim, Il Kyu Lee
  • Patent number: 9233129
    Abstract: Disclosed is a method for the purification of bee venom on a mass scale. It comprises dissolving crude bee venom in a solvent to form a bee venom solution; applying an adsorbent to the bee venom solution to form a mixture; and removing the adsorbent through filtration to afford a pure bee venom solution. By the method of the present invention, crude bee venom collected from bee farms can be purified to a purity of 99% or higher on a mass scale, without inducing a change in the composition thereof, and thus the purified bee venom can be used as a material for medicines, cosmetics and foods.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 12, 2016
    Assignee: Republic of Korea (Management: Rural Development Administration)
    Inventors: Sang Mi Han, Kwang Gill Lee, Kwan Kyu Park
  • Patent number: 9233130
    Abstract: The object of the present invention is a probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the contemporaneous improvement of the intestinal functionality, which can be compromised by therapeutic treatments adopted for re-solving said pathological conditions. Besides that, aim of this invention is a probiotic bacteria-based composition comprising moreover a suitable quantity of at least a substance or nourishment having prebiotic properties and eventually, of suitable pharmacologically active substances.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: January 12, 2016
    Assignee: PROBIOTICAL S.P.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi
  • Patent number: 9233131
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: January 12, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Patent number: 9233132
    Abstract: The invention discloses an engineered oncolytic respiratory syncytial virus (RSV), NS1 gene deficient RSV, and its usage to treat lung cancer by killing cancer cells with in vitro and in vivo evidences.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: January 12, 2016
    Inventors: Weidong Zhang, Lixian Jiang, Calvin Cao
  • Patent number: 9233133
    Abstract: The present invention provides a non-parenteral and non-ocular herbal synergistic detoxifier composition effective for blood purification, blood detoxification and in the treatment and management of disorders related to accumulation of toxins in the body having synergistic effect of its components in specific ratio, better bio availability wherein the amount of dose administered is remarkably low. The formulation of synergistic herbal composition has better patient compliance in the terms of palatability, ease of administration and is formulated in the form of syrup, lozenges/candies/jujubs/mouth freshener, sub-lingual tablets or chewable tablets. The present invention also provides a method of preparation of this formulation.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 12, 2016
    Inventor: Manu Chaudhary
  • Patent number: 9233134
    Abstract: The present invention relates to topical compositions containing fermented extracts of Traditional Chinese Medicinal (TCM) ingredients for improving the appearance and skin condition of the user. The topical compositions of the present invention are tailored for different users of different skin compositions according to TCM principles. The fermented TCM extracts are characterized by reduced odor and/or color in comparison with unfermented TCM extracts and are therefore more suitable for use in cosmetic products.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: January 12, 2016
    Assignee: EL Management LLC
    Inventors: Jing Cheng, Chia-wen Chen, Steven Francis Schnittger, Ming Lu
  • Patent number: 9233135
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 12, 2016
    Assignee: KIDNEY STONE LABORATORIES, INC.
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • Patent number: 9233136
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: January 12, 2016
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Avinash Phadke, Xiangzhu Wang, Suoming Zhang, Atul Agarwal
  • Patent number: 9233137
    Abstract: Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-?1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: January 12, 2016
    Assignee: Celdara Medical, LLC
    Inventors: Ebo D. de Muinck, Jose R. Conejo-Garcia
  • Patent number: 9233138
    Abstract: The present invention includes compounds that are useful for treating or preventing a HIV-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an HIV-1 virus. The presented invention further includes a method of causing virolysis of a virus using the compounds described therein. The presented invention further includes a method of treating or preventing an HIV-1 infection in a mammal in need thereof using the compositions described therein.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 12, 2016
    Assignee: Drexel University
    Inventors: Cameron Frank Abrams, Irwin M. Chaiken, Mark R. Contarino, Bibek Parajuli, Adel Ahmed Rashad Ahmed
  • Patent number: 9233139
    Abstract: As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: January 12, 2016
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Semi Kim, Yunhee Lee
  • Patent number: 9233140
    Abstract: The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: January 12, 2016
    Assignee: Promedior, Inc.
    Inventor: Lynne Anne Murray
  • Patent number: 9233141
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: January 12, 2016
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles